All In Biotech

Drug Trial Radar · NCT05720767

HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study

A Phase 1, Open-label, 2-Part, 2-Period Fixed-Sequence Crossover Study to Assess the Effect of Itraconazole, and the Effect of Rifampin on the Pharmacokinetics of HMPL-523 in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Mar 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

28

Actual

Start

Nov 4, 2022

Primary completion

Feb 5, 2023

Study completion Feb 5, 2023

Sponsor

Lead sponsor
HutchmedIndustry
Sponsor type
Industry
First posted
Feb 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Phase 1, Open-label, 2-Part, 2-Period Fixed-Sequence Crossover Study to Assess the Effect of Itraconazole, a CYP3A and P-glycoprotein Inhibitor, and the Effect of Rifampin, a CYP Enzyme Inducer, on the Pharmacokinetics of HMPL-523 in Healthy Volunteers

Conditions

  • Relapsed or Refractory Lymphoma

Interventions

  • HMPL-523Drug

    HMPL-523 is a selective small-molecule SYK inhibitor.

  • ItraconazoleDrug

    Itraconazole is an FDA approved synthetic triazole antifungal agent

  • RifampinDrug

    Rifampin is an FDA approved semisynthetic antiobiotic derivative indicated in the treatment of both tuberculosis and meningococcal carrier state

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PK parameter for HMPL-523: AUC0-tTime frame: Day 1 to 18
  2. PK parameter for HMPL-523: AUC0-infTime frame: Day 1 to 18
  3. PK parameter for HMPL-523: CmaxTime frame: Day 1 to 18

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PPD Austin

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.